Fang SC, et al. - Researchers evaluated the association of apatinib-induced hypertension (HTN) with clinical outcomes in this retrospective analysis of 110 consecutive patients with advanced non-small-cell lung cancer (NSCLC). HTN was diagnosed in a total of 46 patients (42%). For the hypertensive and normotensive groups, the median progression-free survival (PFS) was 5.6 months and 4.2 months, respectively and the median overall survival (OS) times were 9.9 months and 7.8 months, respectively. Thirty percent of patients in the hypertensive group showed partial response to apatinib vs 6.3% in the non-hypertensive group. In patients with advanced NSCLC , apatinib-induced HTN seems to be an low-cost, valid, and easily measurable biomarker for apatinib antitumor effectiveness.